Juvena hires three new senior executives
Plus: new CEO at ClostraBio, and updates from Cambrian and Pliant
Three months after raising a $41 million series A, human longevity company Juvena Therapeutics Inc. promoted one senior executive and hired three more, to support the expansion of its secreted protein drug discovery platform. The company named Neil Berkley as chief corporate development officer, Gayathri Swaminath as SVP of discovery, Mo Tabrizi as VP of preclinical and non-clinical development, and Eddie Moler as VP of data science. Berkley was CBO at AbCellera Biologics Inc. (NASDAQ:ABCL), Swaminath was VP oncology research & business development at Greenfire Bio, Tabrizi was VP preclinical development at Soteria Biotherapeutics Inc., and Moler joined Juvena last June as head of data science from Spatial Genomics Inc.
Portal Innovations Managing Director Ritu Shah has become CEO of ClostraBio Inc., one of the Chicago firm’s portfolio companies. Shah was formerly COO of Pyxis Oncology Inc. (NASDAQ:PYXS). ClostraBio is developing microbiome-derived metabolites to treat inflammatory bowel disease and food allergy. ...